Acadia Pharmaceuticals 2020 Annual Report

Acadia Pharmaceuticals reported strong 2020 performance with NUPLAZID net sales of $441.8 million, representing 30% year-over-year growth for treating Parkinson's disease psychosis. The company advanced its neuroscience pipeline including Phase 3 programs in Rett syndrome and schizophrenia negative symptoms, while expanding into pain management through the acquisition of CerSci Therapeutics.